Hudson Bay Capital Management
ACRS icon

Hudson Bay Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Hudson Bay Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$635K Buy
120,000
+103,180
+613% +$460K ﹤0.01% 982
2026
Q1 		$63.1K Buy
+16,820
New +$56.8K ﹤0.01% 1224
2025
Q2 		– Sell
-12,200
Closed -$18.7K – 1341
2025
Q1 		$18.7K Buy
+12,200
New +$26K ﹤0.01% 1228

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Hudson Bay Capital Management's ACRS Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Aclaris Therapeutics (ACRS) stake by 613% in Q2 2026, buying an estimated $460K and bringing the position to 120,000 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Hudson Bay Capital Management first reported a position in ACRS in Q1 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Hudson Bay Capital Management held 120,000 shares of Aclaris Therapeutics worth $635K as of Q2 2026.
  • Hudson Bay Capital Management bought 103,180 Aclaris Therapeutics shares in Q2 2026, an estimated $460K.
  • Aclaris Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #982 holding.
  • Hudson Bay Capital Management first reported a position in Aclaris Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.